This is a randomized, open-label, international, multi-center, phase III trial to evaluate
the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line
therapy in patients with advanced HCC.
Locally Advanced or Metastatic and Unresectable HCC
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.